Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)
| Autor: | Ronald Emkey, Kathleen Beusterien, Daiva Masanauskaite, Larry Seidman, Alan Kivitz, William Koltun, Vipul Devas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Osteoporosis Ibandronic acid Drug Administration Schedule law.invention Patient satisfaction Randomized controlled trial law Internal medicine medicine Humans Prospective Studies Prospective cohort study Ibandronic Acid Osteoporosis Postmenopausal Aged Aged 80 and over Cross-Over Studies Alendronate Diphosphonates business.industry fungi food and beverages General Medicine Middle Aged Bisphosphonate medicine.disease Patient preference Crossover study Patient Satisfaction Female business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 21:1895-1903 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/030079905x74862 |
| Popis: | Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered with extended interval dosing. Patient preferences were assessed for once-monthly versus once-weekly bisphosphonate treatment using a previously developed, open-label, cross-over trial design.This was a 6-month, prospective, randomized, open-label, multi-center study with a two-period and two-sequence cross-over treatment design. After screening, eligible patients (postmenopausal women with osteoporosis) were randomized to once-monthly ibandronate 150 mg followed by once-weekly alendronate 70 mg for a total of 6 months (Sequence A) or once-weekly alendronate followed by once-monthly ibandronate for a total of 6 months (Sequence B). The primary objective was to evaluate patient-reported preference for either the once-monthly ibandronate regimen or the once-weekly alendronate regimen based on responses to a preference questionnaire.A total of 342 patients were enrolled into this study (Sequence A, 170; Sequence B, 172). In the primary analysis of patient preference, 71.4% of women selected once-monthly ibandronate and 28.6% of women selected once-weekly alendronate. Overall, 66.1% preferred the once-monthly ibandronate regimen to the once-weekly alendronate regimen (26.5%) and 7.4% of participants stated no preference for either regimen. The preference rate for once-monthly ibandronate was statistically significant (p0.0001). 'Ease of following a treatment regimen for a long time' was the most common reason given for patient preference for both the once-monthly ibandronate (61%, 169/276) and once-weekly alendronate (25%, 70/276) regimens. Additionally, 17% (47/276) of patients who preferred once-monthly ibandronate chose 'it is easier to tolerate side effects' as did 4.3% (12/276) of patients who preferred alendronate. Significantly more women found once-monthly ibandronate to be more convenient (p0.0001).Significantly more women with postmenopausal osteoporosis preferred once-monthly ibandronate therapy to once-weekly alendronate therapy, and found the once-monthly regimen to be more convenient. Ease of following a treatment regimen for a long time was the most common reason given for the patients' preferences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|